ELAN

24.22

3.55% 0.83

Handel nachbörslich: 23.82 -0.40 -1.65%

Elanco Animal Health Inc (ELAN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$23.39

Offen:

$23.845

24-Stunden-Volumen:

10.25M

Relative Volume:

1.64

Marktkapitalisierung:

$12.10B

Einnahmen:

$4.89B

Nettoeinkommen (Verlust:

$-242.00M

KGV:

-49.53

EPS:

-0.489

Netto-Cashflow:

$315.00M

1W Leistung:

+0.71%

1M Leistung:

+21.53%

6M Leistung:

+9.64%

1J Leistung:

+81.70%

1-Tages-Spanne:

$23.68

$24.51

1-Wochen-Bereich:

$23.15

$25.07

52-Wochen-Spanne:

$13.15

$27.72

Elanco Animal Health Inc Stock (ELAN) Company Profile

Firmenname

Elanco Animal Health Inc

Sektor

Healthcare (1104)

Branche

Drug Manufacturers - Specialty & Generic (85)

Telefon

877-352-6261

Adresse

450 ELANCO CIRCLE, INDIANAPOLIS

Mitarbeiter

9,900

Twitter

@Elanco

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

ELAN's Discussions on Twitter

Compare ELAN vs TAK, HLN, TEVA, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ELAN Elanco Animal Health Inc	24.22	12.10B	4.89B	-242.00M	315.00M	-0.489
TAK Takeda Pharmaceutical Co Adr	15.63	49.39B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	8.96	39.55B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.48	36.66B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	78.71	33.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	536.59	22.78B	3.17B	1.29B	1.01B	27.09

Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-15	Eingeleitet	Citigroup	Buy
2026-01-22	Hochstufung	Piper Sandler	Neutral → Overweight
2025-12-09	Eingeleitet	Barclays	Overweight
2025-11-21	Eingeleitet	KeyBanc Capital Markets	Overweight
2025-11-19	Hochstufung	Argus	Hold → Buy
2025-10-07	Hochstufung	JP Morgan	Neutral → Overweight
2025-07-17	Hochstufung	Leerink Partners	Market Perform → Outperform
2025-06-26	Hochstufung	William Blair	Mkt Perform → Outperform
2024-12-09	Eingeleitet	UBS	Buy
2024-12-02	Eingeleitet	Leerink Partners	Market Perform
2024-09-19	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-01-05	Hochstufung	Stifel	Hold → Buy
2023-12-19	Eingeleitet	Jefferies	Buy
2023-12-15	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-12-07	Eingeleitet	Exane BNP Paribas	Outperform
2023-04-20	Hochstufung	Barclays	Equal Weight → Overweight
2022-08-18	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-08-16	Herabstufung	JP Morgan	Overweight → Neutral
2022-07-21	Herabstufung	Goldman	Buy → Sell
2022-07-12	Eingeleitet	Piper Sandler	Neutral
2021-11-18	Eingeleitet	Morgan Stanley	Overweight
2021-10-28	Herabstufung	Stifel	Buy → Hold
2021-08-05	Fortgesetzt	Credit Suisse	Outperform
2021-06-15	Hochstufung	Cleveland Research	Underperform → Neutral
2021-05-11	Hochstufung	Barclays	Underweight → Equal Weight
2021-05-11	Hochstufung	Gabelli & Co	Hold → Buy
2021-04-15	Eingeleitet	Stifel	Buy
2021-03-22	Herabstufung	Gabelli & Co	Buy → Hold
2021-02-26	Hochstufung	Credit Suisse	Neutral → Outperform
2020-12-09	Herabstufung	Argus	Buy → Hold
2020-11-09	Herabstufung	Barclays	Overweight → Underweight
2020-08-20	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-08-13	Fortgesetzt	Credit Suisse	Neutral
2020-08-04	Fortgesetzt	Goldman	Buy
2020-07-27	Herabstufung	Cleveland Research	Neutral → Underperform
2020-04-02	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2020-01-10	Eingeleitet	Raymond James	Mkt Perform
2019-12-19	Hochstufung	BofA/Merrill	Neutral → Buy
2019-11-07	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2019-09-23	Eingeleitet	Barclays	Overweight
2019-08-26	Herabstufung	BofA/Merrill	Buy → Neutral
2019-08-15	Hochstufung	UBS	Sell → Neutral
2019-05-23	Eingeleitet	Guggenheim	Neutral
2019-03-18	Hochstufung	BofA/Merrill	Neutral → Buy
2019-03-13	Fortgesetzt	Morgan Stanley	Equal-Weight
2019-02-12	Eingeleitet	William Blair	Mkt Perform
2019-01-23	Eingeleitet	UBS	Sell
2019-01-15	Eingeleitet	Argus	Buy
2018-10-15	Eingeleitet	Morgan Stanley	Equal-Weight

Alle ansehen

Elanco Animal Health Inc Aktie (ELAN) Neueste Nachrichten

10:23 AM

Neurizon, Elanco Ink Long-Term Supply Agreement for Human Health Monepantel - Contract Pharma

10:23 AM

04:59 AM

T. Rowe Price Investment Management Inc. Increases Position in Elanco Animal Health Incorporated $ELAN - MarketBeat

04:59 AM

02:50 AM

Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

02:50 AM

Jun 18, 2026

ELAN Maintained by TD Cowen -- Price Target Raised to $32 - GuruFocus

Jun 18, 2026

Elanco to launch $25M VC program focused on animal health innovation - Inside INdiana Business

Jun 18, 2026

Elanco Ventures Expands Animal Health Innovation Ecosystem - Kalkine Media

Jun 18, 2026

Elanco (ELAN) Launches Venture Capital Platform for Animal Healt - GuruFocus

Jun 18, 2026

Veterinary API Manufacturing Market to Reach USD 18.48 Billion by 2035 as Animal Health Investments and Zoonotic Disease Prevention Accelerate – SNS Insider - GlobeNewswire Inc.

Jun 18, 2026

TD Cowen Issues Positive Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price - MarketBeat

Jun 18, 2026

TD Cowen raises Elanco Animal Health price target on product launches - Investing.com Canada

Jun 18, 2026

Elanco Animal Health Incorporated Establishes Elanco Ventures Corporate Venture Capital Platform - marketscreener.com

Jun 18, 2026